Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Severe pulmonary hypertension: data from the Swiss Registry
Autore:
Stricker, H; Domenighetti, G; Popov, W; Speich, R; Nicod, L; Aubert, JD; Soler, M;
Indirizzi:
Reg Hosp, CH-6601 Locarno, Switzerland Reg Hosp Locarno Switzerland CH-6601 Hosp, CH-6601 Locarno, Switzerland Univ Zurich Hosp, CH-8091 Zurich, Switzerland Univ Zurich Hosp Zurich Switzerland CH-8091 CH-8091 Zurich, Switzerland Univ Hosp Geneva, Div Pneumol, Geneva, Switzerland Univ Hosp Geneva Geneva Switzerland a, Div Pneumol, Geneva, Switzerland Univ Lausanne Hosp, Div Pneumol, Lausanne, Switzerland Univ Lausanne HospLausanne Switzerland Pneumol, Lausanne, Switzerland Univ Basel Hosp, Dept Pneumol, CH-4031 Basel, Switzerland Univ Basel HospBasel Switzerland CH-4031 ol, CH-4031 Basel, Switzerland
Titolo Testata:
SWISS MEDICAL WEEKLY
fascicolo: 23-24, volume: 131, anno: 2001,
pagine: 346 - 350
SICI:
1424-7860(20010616)131:23-24<346:SPHDFT>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONTINUOUS INTRAVENOUS EPOPROSTENOL; PROSTACYCLIN; TERM; SURVIVAL; ILOPROST; DISEASES; INFUSION; THERAPY;
Keywords:
pulmonary hypertension; registry; aetiology; prognosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Stricker, H Reg Hosp, CH-6601 Locarno, Switzerland Reg Hosp Locarno Switzerland CH-6601 01 Locarno, Switzerland
Citazione:
H. Stricker et al., "Severe pulmonary hypertension: data from the Swiss Registry", SWISS MED W, 131(23-24), 2001, pp. 346-350

Abstract

Background: Severe pulmonary hypertension (PH) is a rare disease with a dismal prognosis if untreated. Progress in diagnosis and in the development of effective therapeutic options has created new interest in this pathology. There are, however, only limited data on the prevalence of severe PH unrelated to chronic left ventricular failure or COPD, on the associated conditions and on the parameters with a prognostic impact. With the aid parameterswith a prog of a retrospective registry we have collected data from 5 centres in Switzerland and attempted to answer the above questions. Methods: Data on patients, with PH from 4 university facilities (Zurich, Basle, Geneva and Lausanne 1) and one well-defined geographical area (Ticino) were retrospectively collected and analysed up to December 1999. Clinicaland haemodynamic parameters and associated diseases were noted. We were also interested in the age distribution of the patients and the year of diagnosis of PH. Results: We found 106 patients with severe PH (43 men, 63 women, median age 43 years); 79% were in NYHA class III or IV. There was a steep rise in diagnosis of PH after 1995. In 74% PH was either primary or associated with collagen vascular disease or thromboembolic disease. By the end of the observation period 30% of the patients had died. The best distinguishing parameters between surviving patients and those who eventually died were the 6-minute walking test (363 vs. 235 metres, p = 0.002), the NYHA class (II vs III/IV,, p = 0.015), and mixed venous saturation (66.5 vs. 57.9%, p = 0.006). Therapy consisted of calcium antagonists in 18% and of (inhaled) prostanoids, chiefly iloprost, in 33 %. Seven patients underwent lung transplantation. Conclusions: We conclude that PH is diagnosed more often as diagnostic andtherapeutic options improve; that primary forms, and those associated withcollagen vascular disease and with chronic venous thromboembolism, make upthree-quarters of the aetiologies; and that the 6-minute walking test, thefunctional class and mixed venous; saturation are the best prognostic parameters.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 02:12:55